Høhloch, Karin

[["dc.bibliographiccitation.firstpage","949"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","British Journal of Haematology"],["dc.bibliographiccitation.lastpage","956"],["dc.bibliographiccitation.volume","184"],["dc.contributor.author","Hohloch, Karin"],["dc.contributor.author","Windemuth-Kieselbach, Christiane"],["dc.contributor.author","Kolz, Julia"],["dc.contributor.author","Zinzani, Pier Luigi"],["dc.contributor.author","Cacchione, Roberto"],["dc.contributor.author","Jurczak, Woijciech"],["dc.contributor.author","Bischof Delaloye, Angelika"],["dc.contributor.author","Trümper, Lorenz"],["dc.contributor.author","Scholz, Christian W."],["dc.date.accessioned","2021-06-01T10:47:12Z"],["dc.date.available","2021-06-01T10:47:12Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1111/bjh.15712"],["dc.identifier.issn","0007-1048"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/85516"],["dc.language.iso","en"],["dc.notes.intern","DOI-Import GROB-425"],["dc.relation.issn","0007-1048"],["dc.title","Radioimmunotherapy (RIT) for Follicular Lymphoma achieves long term lymphoma control in first line and at relapse: 8-year follow-up data of 281 patients from the international RIT-registry"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1585"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","European Journal of Nuclear Medicine and Molecular Imaging"],["dc.bibliographiccitation.lastpage","1592"],["dc.bibliographiccitation.volume","41"],["dc.contributor.author","Hohloch, Karin"],["dc.contributor.author","Lankeit, Henrike Katharina"],["dc.contributor.author","Zinzani, Pier Luigi"],["dc.contributor.author","Scholz, C. W."],["dc.contributor.author","Lorsbach, Michael"],["dc.contributor.author","Windemuth-Kieselbach, C."],["dc.contributor.author","Truemper, Lorenz H."],["dc.date.accessioned","2018-11-07T09:37:21Z"],["dc.date.available","2018-11-07T09:37:21Z"],["dc.date.issued","2014"],["dc.description.abstract","Purpose Very few reliable clinical data about the use of radioimmunotherapy in aggressive B-cell lymphoma exist. Methods Patients with aggressive B-cell lymphoma registered in the international RIT-Network were analysed with regard to prior treatment, response and side effects. The RIT-Network is a web-based registry that collects observational data from radioimmunotherapy-treated patients with malignant lymphoma across 13 countries. Results This analysis included 215 with aggressive B-cell lymphoma out of 232 patients registered in the RIT-Network. Histological subtypes were as follows: 190 diffuse large B-cell, 15 primary mediastinal, 9 anaplastic large cell, and 1 intravascular lymphoma. The median age of the patients was 62 years (range 17 - 88), with 27 % above the age of 70 years. Radioimmunotherapy was mainly used as consolidation after first-line or second-line chemotherapy (56.1 %), as part of third-line to eighth-line therapy for relapse (16.4 %), and in refractory disease (12.2 %). Grade IV neutropenia and thrombopenia and grade III anaemia were observed. The median time to recovery of blood count was 81 days (range 0 - 600 days). The overall response rate was 63.3 %. The complete response rate was 76.4 % in patients treated as part of first-line therapy, and 44.3 % in patients with relapse. Mean overall survival in first-line therapy patients was 32.7 months and 14.0 months in patients with relapse or refractory disease, respectively. Conclusion Most patients with aggressive B-cell lymphoma in the RIT-Network received radioimmunotherapy as consolidation after first-line therapy with excellent complete remission and overall survival rates compared to published data. In relapsed aggressive B-cell lymphoma, radioimmunotherapy is a safe and feasible treatment leading to satisfactory response rates with acceptable toxicity."],["dc.description.sponsorship","Bayer Healthcare"],["dc.identifier.doi","10.1007/s00259-014-2758-y"],["dc.identifier.isi","000339334000014"],["dc.identifier.pmid","24722703"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32822"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1619-7089"],["dc.relation.issn","1619-7070"],["dc.title","Radioimmunotherapy for first-line and relapse treatment of aggressive B-cell non-Hodgkin lymphoma: an analysis of 215 patients registered in the international RIT-Network"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1073"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Annals of Hematology"],["dc.bibliographiccitation.lastpage","1079"],["dc.bibliographiccitation.volume","99"],["dc.contributor.author","Hohloch, Karin"],["dc.contributor.author","Windemuth-Kieselbach, Christine"],["dc.contributor.author","Zinzani, Pier Luigi"],["dc.contributor.author","Cacchione, Roberto"],["dc.contributor.author","Jurczak, Wojciech"],["dc.contributor.author","Suh, C."],["dc.contributor.author","Trümper, Lorenz"],["dc.contributor.author","Scholz, Christian W."],["dc.date.accessioned","2020-12-10T14:10:06Z"],["dc.date.available","2020-12-10T14:10:06Z"],["dc.date.issued","2020"],["dc.identifier.doi","10.1007/s00277-020-03956-0"],["dc.identifier.eissn","1432-0584"],["dc.identifier.issn","0939-5555"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/70648"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Radioimmunotherapy for mantle cell lymphoma: 5-year follow-up of 90 patients from the international RIT registry"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","901"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Bone Marrow Transplantation"],["dc.bibliographiccitation.lastpage","903"],["dc.bibliographiccitation.volume","46"],["dc.contributor.author","Hohloch, Karin"],["dc.contributor.author","Zinzani, Pier Luigi"],["dc.contributor.author","Linkesch, Werner"],["dc.contributor.author","Jurczak, Wojciech"],["dc.contributor.author","Deptala, Andrzej"],["dc.contributor.author","Lorsbach, Michael"],["dc.contributor.author","Windemuth-Kiesselbach, Christiane"],["dc.contributor.author","Wulf, Gerald G."],["dc.contributor.author","Truemper, Lorenz H."],["dc.date.accessioned","2018-11-07T08:55:32Z"],["dc.date.available","2018-11-07T08:55:32Z"],["dc.date.issued","2011"],["dc.identifier.doi","10.1038/bmt.2010.202"],["dc.identifier.isi","000291383100021"],["dc.identifier.pmid","20871640"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/22929"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Nature Publishing Group"],["dc.relation.issn","0268-3369"],["dc.title","Radioimmunotherapy with Y-90-ibritumomab tiuxetan is a safe and efficient treatment for patients with B-cell lymphoma relapsed after auto-SCT: an analysis of the international RIT-Network"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.subtype","letter_note"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","15"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.volume","28"],["dc.contributor.author","Hohloch, Karin"],["dc.contributor.author","Windermuth-Kiesselbach, C."],["dc.contributor.author","Lorsbach, Michael"],["dc.contributor.author","Zinzani, Pier Luigi"],["dc.contributor.author","Truemper, Lorenz H."],["dc.date.accessioned","2018-11-07T08:43:10Z"],["dc.date.available","2018-11-07T08:43:10Z"],["dc.date.issued","2010"],["dc.identifier.isi","000208852005125"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/19894"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Clinical Oncology"],["dc.publisher.place","Alexandria"],["dc.relation.issn","1527-7755"],["dc.relation.issn","0732-183X"],["dc.title","Radioimmunotherapy for consolidation and relapse therapy for aggressive B-cell non-Hodgkin lymphoma: Retrospective analysis of the International RIT-Network."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","15"],["dc.bibliographiccitation.journal","Journal of Clinical Oncology"],["dc.bibliographiccitation.volume","30"],["dc.contributor.author","Hohloch, Karin"],["dc.contributor.author","Lankeit, Henrike Katharina"],["dc.contributor.author","Zinzani, Pier Luigi"],["dc.contributor.author","Lorsbach, Michael"],["dc.contributor.author","Windemuth-Kiesselbach, Christiane"],["dc.contributor.author","Truemper, Lorenz H."],["dc.date.accessioned","2018-11-07T09:10:21Z"],["dc.date.available","2018-11-07T09:10:21Z"],["dc.date.issued","2012"],["dc.identifier.isi","000318009803719"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/26465"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Clinical Oncology"],["dc.publisher.place","Alexandria"],["dc.relation.conference","48th Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)"],["dc.relation.eventlocation","Chicago, IL"],["dc.relation.issn","0732-183X"],["dc.title","Radioimmunotherapy efficiency and safety in consolidation and relapse treatment of aggressive B-cell non-Hodgkin lymphoma: An updated analysis of 230 patients of the international RIT-network."],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","11"],["dc.bibliographiccitation.journal","Blood"],["dc.bibliographiccitation.volume","112"],["dc.contributor.author","Hohloh, Karin"],["dc.contributor.author","Zinzani, Pier Luigi"],["dc.contributor.author","Linkesch, Werner, Jr."],["dc.contributor.author","Deptala, Andrzej"],["dc.contributor.author","Wojciech, Jurczak"],["dc.contributor.author","Suh, Cheolwon"],["dc.contributor.author","Lorsbach, Michael"],["dc.contributor.author","Windemuth-Kiesselbach, Christiane"],["dc.contributor.author","Truemper, Lorenz H."],["dc.date.accessioned","2018-11-07T11:09:06Z"],["dc.date.available","2018-11-07T11:09:06Z"],["dc.date.issued","2008"],["dc.format.extent","1053"],["dc.identifier.isi","000262104703501"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/52934"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Amer Soc Hematology"],["dc.publisher.place","Washington"],["dc.relation.conference","50th Annual Meeting of the American-Society-of-Hematology"],["dc.relation.eventlocation","San Francisco, CA"],["dc.relation.issn","0006-4971"],["dc.title","Radioimmunotherapy Is Safe and Effective in Relapse after Stem Cell Transplantation for B-Cell Non Hodgkins Lymphoma, An Analysis of the International RIT-Network"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Annals of Oncology"],["dc.bibliographiccitation.volume","19"],["dc.contributor.author","Hohloch, Karin"],["dc.contributor.author","Lorsbach, Michael"],["dc.contributor.author","Zinzani, Pier Luigi"],["dc.contributor.author","Chairman, N."],["dc.contributor.author","Truemper, Lorenz H."],["dc.date.accessioned","2018-11-07T11:14:10Z"],["dc.date.available","2018-11-07T11:14:10Z"],["dc.date.issued","2008"],["dc.format.extent","184"],["dc.identifier.isi","000256693500358"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/54065"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Oxford Univ Press"],["dc.publisher.place","Oxford"],["dc.relation.conference","10th International Conference on Malignant Lymphoma"],["dc.relation.eventlocation","Lugano, SWITZERLAND"],["dc.relation.issn","0923-7534"],["dc.title","The RIT Network provides real life clinical data on radioimmunotherapy for lymphoma: An international registry for radioimmunotherapy-treated patients"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Annals of Oncology"],["dc.bibliographiccitation.volume","22"],["dc.contributor.author","Hohloch, Karin"],["dc.contributor.author","Lankeit, Henrike Katharina"],["dc.contributor.author","Zinzani, Pier Luigi"],["dc.contributor.author","Lorsbach, Michael"],["dc.contributor.author","Windemuth-Kiesselbach, Christiane"],["dc.contributor.author","Truemper, Lorenz H."],["dc.date.accessioned","2018-11-07T08:55:46Z"],["dc.date.available","2018-11-07T08:55:46Z"],["dc.date.issued","2011"],["dc.format.extent","225"],["dc.identifier.isi","000291996300447"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/22982"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Oxford Univ Press"],["dc.publisher.place","Oxford"],["dc.relation.conference","11th International Conference on Malignant Lymphoma"],["dc.relation.eventlocation","Lugano, SWITZERLAND"],["dc.relation.issn","1569-8041"],["dc.relation.issn","0923-7534"],["dc.title","RADIOIMMUNOTHERAPY FOR CONSOLIDATION AND RELAPSE TREATMENT OF AGGRESSIVE B-CELL NON HODGKINS LYMPHOMA: AN UPDATED ANALYSIS OF THE INTERNATIONAL RIT-NETWORK"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","1354"],["dc.bibliographiccitation.issue","9"],["dc.bibliographiccitation.journal","Journal of Nuclear Medicine"],["dc.bibliographiccitation.lastpage","1360"],["dc.bibliographiccitation.volume","52"],["dc.contributor.author","Hohloch, Karin"],["dc.contributor.author","Delaloye, Angelika Bischof"],["dc.contributor.author","Windemuth-Kieselbach, Christiane"],["dc.contributor.author","Gomez-Codina, Jose"],["dc.contributor.author","Linkesch, Werner"],["dc.contributor.author","Jurczak, Woijciech"],["dc.contributor.author","Cacchione, Roberto"],["dc.contributor.author","Suh, Cheolwon"],["dc.contributor.author","Zinzani, Pier Luigi"],["dc.contributor.author","Truemper, Lorenz H."],["dc.date.accessioned","2018-11-07T08:52:44Z"],["dc.date.available","2018-11-07T08:52:44Z"],["dc.date.issued","2011"],["dc.description.abstract","The Radioimmunotherapy Network (RIT-N) is a Web-based, international registry collecting long-term observational data about radioimmunotherapy-treated patients with malignant lymphoma outside randomized clinical studies. The RIT-N collects unbiased data on treatment indications, disease stages, patients' conditions, lymphoma subtypes, and hematologic side effects of radioimmunotherapy treatment. Methods: RIT-N is located at the University of Gottingen, Germany, and collected data from 14 countries. Data were entered by investigators into a Web-based central database managed by an independent clinical research organization. Results: Patients (1,075) were enrolled from December 2006 until November 2009, and 467 patients with an observation time of at least 12 mo were included in the following analysis. Diagnoses were as follows: 58% follicular lymphoma and 42% other B-cell lymphomas. The mean overall survival was 28 mo for follicular lymphoma and 26 mo for other lymphoma subtypes. Hematotoxicity was mild for hemoglobin (World Health Organization grade II), with a median nadir of 10 g/dL, but severe (World Health Organization grade III) for platelets and leukocytes, with a median nadir of 7,000/mu L and 2.2/mu L, respectively. Conclusion: Clinical usage of radioimmunotherapy differs from the labeled indications and can be assessed by this registry, enabling analyses of outcome and toxicity data beyond clinical trials. This analysis proves that radioimmunotherapy in follicular lymphoma and other lymphoma subtypes is a safe and efficient treatment option."],["dc.identifier.doi","10.2967/jnumed.111.089920"],["dc.identifier.isi","000294480900028"],["dc.identifier.pmid","21828114"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/22243"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Soc Nuclear Medicine Inc"],["dc.relation.issn","0161-5505"],["dc.title","Radioimmunotherapy Confers Long-Term Survival to Lymphoma Patients with Acceptable Toxicity: Registry Analysis by the International Radioimmunotherapy Network"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]